Healthy Males Clinical Trial
Official title:
The Influence of Cerebral Blood Flow and PETCO2 on Neuromuscular Function During Passive Heat Stress
Verified date | January 2018 |
Source | Brock University |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Increased core temperature (hyperthermia) has been associated with impaired neuromuscular
performance; however, the mechanisms associated with these performance decrements and their
potential synergies remain unclear. While the majority of research suggests that the observed
fatigue is related to the central nervous system, the influence of changes in cerebral blood
flow (CBF) and associated changes in cerebral alkalosis (estimated by end-tidal partial
pressure of carbon dioxide; PETCO2) remains unexamined. In response to hyperthermia, humans
hyperventilate as means of heat dissipation, resulting in a hypocapnia (reduced PETCO2)
mediated decrease in CBF and consequently, cerebral alkalosis (increased cerebral pH).
Previous research suggests that hyperventilation induces changes in neural excitability and
synaptic transmission; however, it remains unclear if these changes are related to hypocapnia
mediated decrease in CBF or decreased PETCO2 or both.
The purpose of the proposed research program is to examine the influence of changes in CBF
and cerebral alkalosis on neuromuscular function during passive heat stress. The research
project will consist of 3 separate experimental trials: (a) poikilocapnic hyperthermia
(increased core temperature; decrease CBF; decrease PETCO2), (b) isocapnic hyperthermia
(increased core temperature; no change CBF; no change PETCO2) and (c) isocapnic hyperthermia
+ indomethacin (increased core temperature; decrease CBF; no change PETCO2). During each
manipulation, neuromuscular function will be evaluated and compared to baseline
(normothermic) conditions using a repeated measures design.
It is hypothesized that changes in PETCO2 and therefore, changes in cerebral alkalosis will
contribute to neuromuscular fatigue independent of changes in CBF or increases in core
temperature.
Status | Completed |
Enrollment | 8 |
Est. completion date | December 2016 |
Est. primary completion date | June 2015 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | Male |
Age group | 18 Years to 45 Years |
Eligibility |
Inclusion Criteria: - 18 to 45 yrs old; healthy males Exclusion Criteria: - diagnosed medical condition; NSAID allergy; smoker; high altitude exposure; implants |
Country | Name | City | State |
---|---|---|---|
Canada | Brock University | St Catharines | Ontario |
Lead Sponsor | Collaborator |
---|---|
Brock University |
Canada,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Resting motor threshold | Motor evoked potentials are recorded from muscles following transcranial magnetic stimulation of motor cortex. The resting motor threshold is defined as the minimum stimulation intensity required to elicit a motor evoked potential. Resting motor threshold will be quantified in millivolts. | Change from baseline 90-minutes | |
Primary | H-Reflex Amplitude | The H-Reflex is an indirect measure of motor neuron excitability. Initially, a maximal M-wave (M-max) will be elicited by stimulating (1 ms in duration; 15 s between stimuli) the median nerve incrementally (2 V increments) until the largest waveform is observed. The peak-to-peak amplitude of this waveform is considered M-max. Using similar procedures as above, a sub-maximal M-wave of 5% M-max will be elicited and the amplitude of the resultant H-reflex (a small waveform observed following the submaximal M-wave) will be calculated. The amplitude of the H-reflex will be quantified in millivolts. | Change from baseline 90-minutes | |
Primary | Maximal Voluntary Contraction | During maximal voluntary contraction (MVC) testing, the participants' right arm will be secured in a custom made device used to isolate forearm flexion and to measure force production by the flexor carpi radialis muscle. Participants will be asked to produce a 5-second MVC and will be verbally encouraged to maintain maximal force production throughout the duration of the contraction. MVC will be quantified as the maximum force production in newton meters. | Change from baseline 90-minutes | |
Primary | H-Reflex latency | The H-Reflex is an indirect measure of motor neuron excitability. Initially, a maximal M-wave (M-max) will be elicited by stimulating (1 ms in duration; 15 s between stimuli) the median nerve incrementally (2 V increments) until the largest waveform is observed. The peak-to-peak amplitude of this waveform is considered M-max. Using similar procedures as above, a sub-maximal M-wave of 5% M-max will be elicited and the amplitude of the resultant H-reflex (a small waveform observed following the submaximal M-wave) will be calculated. The onset latency of the H-reflex will be quantified in milliseconds. | Change from baseline 90-minutes | |
Primary | Voluntary Activation | The level of neural drive to muscle during contraction is termed voluntary activation and will be estimated by interpolation of a single supramaximal motor evoked potential during the 5-second MVC contraction. If extra force is evoked by the 'superimposed' stimulus then either the stimulated axons were not all recruited voluntarily or they were discharging at sub-tetanic rates. Therefore, voluntary activation will be quantified as the amplitude of maximal voluntary force production, relative to the amplitude of the supramaximal MEP. | change from baseline 90-minutes | |
Secondary | Middle Cerebral Artery Blood Flow Velocity | Middle cerebral artery (MCA) blood flow velocity will be measured non-invasively by a 2-MHz transcranial Doppler (TCD) ultrasound probe, attached bilaterally to a comfortable headband and secured anterior to the zygomatic arch, rostral of the pinna. Doppler probes will be paced over the temporal windows (near the ear) and will remain in place throughout the duration of the experimental protocol. MCA velocity will be quantified in cm/s. | Change from baseline 90-minutes | |
Secondary | Blood Pressure | Beat by beat blood pressure will be calculated from the blood pressure waveform using finger photoplethysmography (Nexfin, bmeye), with a finger cuff placed directly over the middle finger on the left hand. Blood pressure will be quantified in mmHg. | Change from baseline 90-minutes | |
Secondary | Heart rate | Heart rate will be measured by electrocardiogram. Heart rate will be quantified in beats per minute. | Change from baseline 90-minutes | |
Secondary | End-tidal Gas concentrations | The end-tidal concentrations of oxygen and carbon dioxide will be measured and reported in mmHg. | change from baseline 90-minutes | |
Secondary | Rectal Temperature | Rectal temperature will be measured in degrees Celsius | change from baseline 90-minutes | |
Secondary | Skin Temperature | skin temperature will be measured in degrees Celsius | change from baseline 90-minutes |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04234594 -
Comparing the Pharmacokinetic and Safety of QL1203 and Vectibix® in Healthy Males.
|
Phase 1 | |
Completed |
NCT01367561 -
Naloxone and Intravenous Methylnaltrexone Effects on Bladder Function
|
Phase 1 | |
Completed |
NCT00777543 -
Increasing Ferulic Acid Bioavailability in Bran
|
N/A | |
Recruiting |
NCT04756635 -
Effects of Short- Term Intermittent Fasting Aerobic and Anaerobic Capacity
|
N/A | |
Completed |
NCT02156661 -
Oxytocin and Emotion Processing
|
Phase 1 | |
Completed |
NCT05294198 -
Beetroot Extract and Its Influence on Cardiovascular and Autonomic Recovery From the Effort in Healthy Males
|
N/A | |
Completed |
NCT00839319 -
HOP-3 Manipulation of the Intratesticular Hormonal Milieu With Exogenous Testosterone
|
Phase 1/Phase 2 | |
Completed |
NCT00842751 -
Oral T7 Oral Testosterone in Man
|
Phase 2 | |
Completed |
NCT01847053 -
Bioavailability Study of Cinnamon in Healthy Subjects
|
Phase 1/Phase 2 | |
Completed |
NCT01215292 -
ITT4 Intratesticular Hormonal Milieu in Man (ITT4)
|
Phase 1/Phase 2 | |
Completed |
NCT00782392 -
Bioavailability and Dosing of a Monosaccharide Supplement in Adults
|
N/A | |
Completed |
NCT03714685 -
Evaluation of the PK Profile of Firibastat Following Administration of Firibastat Prototype Tablet Formulations
|
Phase 1 | |
Completed |
NCT05277597 -
Effect of a 4-week Post-exercise Sauna Bathing on Targeted Gut Microbiota
|
N/A | |
Completed |
NCT01032616 -
Uptake and Utilization of Amino Acids by Splanchnic Bed
|
Phase 1 | |
Completed |
NCT01830335 -
Cerebral Blood Flow and PETCO2 on Neuromuscular Function During Environmental Stress
|
Phase 4 | |
Completed |
NCT00902512 -
Study Of Bioavailability Of Two Sildenafil 100mg Oral Tablet Formulations
|
Phase 4 | |
Completed |
NCT00475371 -
A First in Human, Single Dose, Safety and Tolerability Study of MKC253 Inhalation Powder in Healthy Adult Males
|
Phase 1 | |
Completed |
NCT01870102 -
Phase 1 Study to Compare the Pharmacokinetic Characteristics and Food Effect of Pelubiprofen (30mg) Tablet IR and Pelubiprofen SR (as a Pelubiprofen 45 mg) Tablet in Healthy Subjects
|
Phase 1 |